STAT3/NF‐κB signalling disruption in M2 tumour‐associated macrophages is a major target of PLGA nanocarriers/PD‐L1 antibody immunomodulatory therapy in breast cancer

Cavalcante, RômuloIshikawa, UtaSilva, EmanuellSilva Jr, ArnóbioAraújo, AurigenaCruz, LuisChan, AlanAraújo Jr, Raimundo2022-10-072022-10-072021-03-31Cavalcante, R. S., Ishikawa, U., Silva, E. S., Silva-Júnior, A. A., Araújo, A. A., Cruz, L. J., Chan, A. B., & de Araújo Júnior, R. F. STAT3/NF-κB signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers/PD-L1 antibody immunomodulatory therapy in breast cancer. Br J Pharmacol. 2021;178(11):2284-2304. doi:10.1111/bph.15373https://repositorio.ufrn.br/handle/123456789/49513ImmunomodulationM2‐like macrophagesNF‐κBPD‐L1 antibodyPLGA nanoparticlesSTAT3tumour microenvironmentSTAT3/NF‐κB signalling disruption in M2 tumour‐associated macrophages is a major target of PLGA nanocarriers/PD‐L1 antibody immunomodulatory therapy in breast cancerSTAT3/NF‐κB signalling disruption in M2 tumour‐associated macrophages is a major target of PLGA nanocarriers/PD‐L1 antibody immunomodulatory therapy in breast cancerarticle10.1111/bph.15373